• About us
• Contact

Advertisement

Organisation › Details

University of Texas, Southwestern Medical Center (UT Southwestern, Dallas)

UT Southwestern Medical Center, one of the premier medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. Its more than 1,400 full-time faculty members - including four active Nobel Prize winners, more than any other medical school in the world - are responsible for groundbreaking medical advances and are committed to translating science-driven research quickly to new clinical treatments. UT Southwestern physicians provide medical care in 40 specialties to nearly 89,000 hospitalized patients and oversee 2.1 million outpatient visits a year. *

 

	Start	2000-09-01 existent
	Group	University of Texas System
	Industry	science
	Region	Dallas, TX
	Country	United States (USA)
	Street	5323 Harry Hines Blvd.
	City	75390 Dallas, TX
	Tel	+1-214-648-3111
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«:
		Record changed: 2021-10-24

Advertisement

More documents for University of Texas System

• [1] ImmunOs Therapeutics AG. (4/25/23). "Press Release: ImmunOs Therapeutics Appoints Michael A. Curran, PhD, as Chairman of its Scientific Advisory Board". Schlieren & Gaithersburg, MD....
• [2] Affimed N.V.. (4/10/22). "Press Release: Affimed Presents Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at AACR Annual Meeting". Heidelberg....
• [3] Valo Health LLC. (11/10/20). "Press Release: Valo Health Adds Award-Winning Neurobiologist Virginie Buggia-Prevot Ph.D. and Computational Scientist Andrea Rossi Ph.D.". Boston, MA....
• [4] NBE Therapeutics AG. (10/26/20). "Press Release: NBE-Therapeutics Commences First Clinical Study of Anti-ROR1 Antibody-Drug Conjugate for Patients with Solid Tumors". Basel....
• [5] Taysha Gene Therapies. (4/29/20). "Press Release: Taysha Gene Therapies Launches with $30 Million Seed Financing and Unrivaled Strategic Partnership with the UT Southwestern Gene Therapy Program". Dallas, TX....
• [6] Artios Pharma Ltd.. (11/6/19). "Press Release: Artios Pharma, MD Anderson and ShangPharma Announce In-licensing Agreement for DNA Damage Response Inhibitor". Cambridge, New York, NY, Houston, TX & South San Franicsco, CA....
• [7] Cellectis S.A.. (10/29/19). "Press Release: First Patient Dosed with Off-the-Shelf UCARTCS1 Product Candidate for Relapsed/Refractory Multiple Myeloma". New York, NY....
• [8] Boehringer Ingelheim. (8/12/19). "Press Release: Boehringer Ingelheim and MD Anderson Form Unique Virtual Research and Development Center to Rapidly Advance New Cancer Therapies". Ingelheim....
• [9] Adaptimmune Therapeutics plc. (7/22/19). "Press Release: Adaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer Center". Philadeliphia, PA & Oxfordshire....
• [10] Nanobiotix S.A.. (4/2/19). "Press Release: Combination of First-in-Class NBTXR3, Radiotherapy, and Anti-PD-1 Immunotherapy Demonstrate Efficacy in Treating Resistant Pre-clinical in Vivo Models of Lung Cancer". Paris & Cambridge, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.